KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks

Ben Palleiko is asked about the company's take on headlines that were in the news during the FDA review of the drug, and he describes the need for an oral therapy and the company's commercial strategy now that the approval is in hand.